U.K. agency backs Boehringer's Pradaxa to prevent stroke in some

03/15/2012 | Bloomberg

Boehringer Ingelheim gained support of the U.K. National Institute for Health and Clinical Excellence for anti-clotting drug Pradaxa to prevent stroke and systemic embolism in people with atrial fibrillation. The agency said Pradaxa is a "useful alternative option" because it doesn't require frequent blood monitoring. Patients should be informed about the usage's risks and benefits compared with warfarin before starting therapy, the agency said.

View Full Article in:

Bloomberg

Published in Brief: